Proposal concerning members of the Board

Proposal concerning members of the Board

Supplement to the notice of the Annual General Meeting to be held on April 29,
2008

Vitrolife's election committee has in the notice to attend the Annual General
Meeting on March 28, 2008 proposed that the members of the Board shall be five
or six in number, without any deputies, and that the Board shall consist of the
following members: Patrik Tigerschiöld (re-election), Madeleine Olsson-Eriksson
(re-election), Semmy Rülf (re-election), Fredrik Mattsson (re-election) and
Maris Hartmanis (new election). A presentation of Maris Hartmanis was made in
the notice to attend the Annual General Meeting.

The election committee proposes Tord Lendau as the sixth member of the Board.
Tord Lendau was born in 1957 and is today managing director of product area
MedTech within Sandvik. Tord has previously been the CEO of Artimplant AB and he
has also worked in senior positions in, for example, Noster Systems AB and
Medtronic/Synectics. Today he is also a member of the Board for Nasdaq-listed
ArthroCare, Inc. Tord Lendau does not own any shares in Vitrolife.

The company has been informed that shareholders representing approximately 38
percent of the shares and votes in the company support the proposal of the
election committee.


April 16, 2008
Kungsbacka, Sweden 

The Board






Queries should be addressed to: 
Magnus Nilsson, CEO, phone +46 31 721 80 00 or +46 708 22 80 61.
Anna Ahlberg, CFO, phone +46 31 721 80 13 or +46 708 22 80 13.


________________________________________________________________________________
_________
Vitrolife is a global biotechnology/medical device Group that works with
developing, manufacturing and selling advanced products and systems for the
preparation, cultivation and storage of human cells, tissue and organs. The
company has business activities within three product areas: Fertility,
Transplantation and Stem Cell Cultivation. The Fertility product area works with
nutrient solutions (media) and advanced consumable instruments such as needles
and pipettes, for the treatment of human infertility. The Transplantation
product area works with solutions and systems to maintain tissue in optimal
condition outside the body for the required time while waiting for
transplantation. The Stem Cell Cultivation product area works with media and
instruments to enable the use and handling of stem cells for therapeutic
purposes. 
     Vitrolife today has approximately 140 employees and the company's products
are sold in more than 80 markets. The head office is in Kungsbacka, Sweden, and
there are subsidiaries in Sweden, USA, Australia and Italy. The Vitrolife share
is listed on the OMX Nordic Exchange's Nordic Small Cap list.
________________________________________________________________________________
_________
Vitrolife AB (publ), Faktorvägen 13, SE-434 37 Kungsbacka, Sweden. Corporate
identity number 556354-3452.
Tel: +46 31 721 80 00. Fax: +46 31 721 80 90. E-mail: info@vitrolife.com.
Homepage: www.vitrolife.com.

The information in this press release is such as that which Vitrolife is
required to publish in accordance with the Securities Exchange and Clearing
Operations Act.

This is a translation of the Swedish version of the press release. When in
doubt, the Swedish wording prevails.